Progressive alterations in global and GC-rich DNA methylation during tumorigenesis.
DNA methylation plays a key role in the regulation of gene expression, and failure to maintain normal patterns of methylation often contributes to carcinogenesis. We have characterized progressive methylation changes during the promotion stage of carcinogenesis using a SENCAR mouse skin initiation/promotion tumorigenesis model. Mice were initiated with a dermal application of 75 microg dimethylbenz[a]anthracene (DMBA) and promoted with 9, 18, 27, and 36 mg cigarette smoke condensate (CSC) thrice weekly for time periods up to 29 weeks, when a large increase in tumor number was produced by the highest three doses. Global and GC-specific methylation were assessed using SssI methylase and arbitrarily primed PCR, respectively. Changes in GC-specific methylation were dose- and time-dependent. CSC doses required to detect these changes were 27 mg at 6 weeks and 18 mg at 9 weeks. This effect appears to be reversible; changes in GC-specific methylation were less marked after 9 weeks promotion with 27 mg CSC followed by 6 weeks of recovery in comparison to 9 and 15 weeks promotion with 27 mg CSC and no recovery period. Both tumor and non-tumor tissue promoted with 27 mg CSC for 29 weeks exhibited changes in GC-specific methylation that were more pronounced in tumors. Tumor tissue was globally hypomethylated, whereas non-tumor tissue did not exhibit changes in global methylation. In conclusion, as expected for a mechanism underlying tumor promotion, CSC alters methylation in a threshold-exhibiting, reversible, progressive fashion during promotion. Progressive alterations in global and GC-rich methylation appear to be mechanistically important during tumor promotion.
Watson
Rebecca E
RE
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan 48824, USA.
Curtin
Geoffrey M
GM
Doolittle
David J
DJ
Goodman
Jay I
JI
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity; D000818:Animals; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000737:chemistry / Q000633:toxicity*; D003596:Cytosine; D019175:DNA Methylation / Q000187:drug effects*; D004273:DNA, Neoplasm / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D020022:Genetic Predisposition to Disease; D006151:Guanosine; D051379:Mice; D018632:Mice, Inbred SENCAR; D016133:Polymerase Chain Reaction; D020127:Recovery of Function; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000235:genetics / Q000473:pathology; D012906:Smoke / Q000009:adverse effects* / Q000032:analysis; D013638:Tars / Q000737:chemistry / Q000633:toxicity*
D002273:Carcinogens; D004273:DNA, Neoplasm; D012906:Smoke; D013638:Tars; C024746:tobacco tar; D006151:Guanosine; D015127:9,10-Dimethyl-1,2-benzanthracene; D003596:Cytosine